Pharmaceutical News and Articles

FDA Approves Expanded Age Indication for GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk

People Sickened in 4 States After Eating Diamond Shruumz Microdosing Chocolate Bars

The U.S. Food and Drug Administration is warning Americans to avoid Diamond Shruumz-brand Microdosing Chocolate Bars, after numerous people have been made sick

Moderna Announces Good Results From Trial of Combo COVID/Flu Vaccine

An experimental vaccine that could offer one-stop prevention for both COVID-19 and influenza is showing positive results among older adults in trials, maker Mod

FDA Gives Nod to RSV Vaccine, Arexvy, for People in Their 50s

The U.S. Food and Drug Administration on Friday has for the first time approved the use of a respiratory syncytial virus (RSV) vaccine for people in their 50s w

Study Supports Safety of High-Dose General Anesthesia

in the first five days after surgery. They had similar complication rates, length of hospital stays and risk of premature death for a year after surgery. Signif

Just 18% of People Who Need Lung Cancer Screening Get It

Only a fraction of Americans are getting recommended lung cancer screenings, new research shows. While rates overall are up slightly, fewer than 1 in 5 people w

Bulevirtide + Peginterferon Alfa-2a Best Treatment for Chronic Hepatitis D

The combination of bulevirtide plus peginterferon alfa-2a is superior to bulevirtide monotherapy for achieving undetectable hepatitis D virus (HDV) RNA level at

Planetary Health Diet Index Linked to Lower Total, Cause-Specific Mortality

A higher Planetary Health Diet Index (PHDI) is associated with a lower risk for total and cause-specific mortality, according to a study published online June 1

American Society of Clinical Oncology, May 30-June 4

The annual meeting of the American Society of Clinical Oncology was held from May 30 to June 4 in Chicago and hosted more than 34,000 participants from around t

Insulin-Treated T2D Patients Unwilling to Participate in Intensive Lifestyle Intervention

For adults with advanced, insulin-treated type 2 diabetes (T2D), willingness to participate in an intensive lifestyle intervention (ILI) is very low, according